查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1939557

人工生物瓣膜市場：依組織材料、植入方法、瓣膜位置和最終用戶分類，全球預測，2026-2032年

Artificial Biological Valve Market by Tissue Material, Implantation Method, Valve Position, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，人工生物瓣膜市場價值將達到 83 億美元，到 2026 年將成長至 87.2 億美元，到 2032 年將達到 119.3 億美元，複合年成長率為 5.32%。

主要市場統計數據
基準年 2025 83億美元
預計年份：2026年 87.2億美元
預測年份：2032年 119.3億美元
複合年成長率 (%) 5.32%

這份精闢的概述定義了生物瓣膜治療的未來，清楚地闡述了臨床需求、材料創新和策略決策促進因素。

人工生物瓣膜市場正處於轉折點，其促進因素包括臨床需求的整合、技術創新以及治療管道的演變。本執行摘要整合了多學科的洞見，旨在幫助臨床醫生、製造商、支付方和投資者了解影響瓣膜選擇、部署方式和生命週期管理的關鍵因素。本概要並非著重於原始數據，而是聚焦於結構性促進因素、營運影響以及已被證明在不同醫療體系中最有效的策略因應措施。

全面審視材料科學的突破、製程創新以及不斷變化的法規環境如何重新定義瓣膜治療的臨床途徑和商業性價值

組織瓣膜領域正經歷變革時期，這場變革超越了產品性能的漸進式改進，從根本上改變了瓣膜的研發、選擇和交付方式。組織處理和保存技術的進步降低了瓣膜的即時免疫抗原性，延長了其功能壽命；而新型抗鈣化化學方法和基質穩定技術則改變了人們對瓣膜長期性能的預期。同時，成像技術、計算建模和器械尺寸設計的改進使得手術全期規劃更加精準，併發症率降低，從而促進了微創手術方式的普及。

基於證據的分析，探討2025年關稅調整如何重塑生物瓣膜採購、生產在地化和臨床採購的動態。

2025年實施的新關稅對組織瓣膜領域的供應鏈、籌資策略和定價結構產生了連鎖反應。在貿易層面，進口組織加工材料和成品組織瓣膜組件關稅的提高增加了到岸成本，迫使許多製造商重新評估其籌資策略。因此，採購團隊轉向更多元化的供應商基礎，並在可能的情況下進行近岸外包；而臨床團隊則加強了與供應商的合作，以穩定前置作業時間並確保服務承諾。

一種將組織基質、手術通道、解剖目標和臨床環境與產品設計和市場策略要求聯繫起來的多層分割觀點

了解市場區隔對於解讀生物瓣膜市場的需求促進因素和創新重點至關重要。從組織材料、植入方法、瓣膜位置和最終用戶等多層次觀點，可以揭示產品設計和商業化的不同需求。同種異體移植和異質骨移植之間組織材料的差異造就了不同的研發路徑。冷凍保存或去細胞的同種異體移植強調免疫相容性和維持天然幾何形狀，而含有牛或豬基質的異質骨移植則優先考慮可擴展性和標準化處理通訊協定。這些材料選擇會對手術流程產生影響，因為保存的人體組織和永續來源的動物源性瓣膜葉片在組織處理、儲存要求和術中表現方面存在差異。

對全球醫療保健系統中閥門創新推廣規模的影響，進行區域性評估，包括採納、報銷和生產策略。

區域趨勢將影響組織瓣膜技術創新成果的採納、報銷和支持。對美洲、歐洲、中東和非洲以及亞太地區的比較觀點突顯了各地區的機會和挑戰。在美洲，臨床系統優先考慮手術流程和治療結果的透明度，而整合醫療網路則優先考慮能夠縮短住院時間和降低再入院風險的技術。該地區的醫生和管理人員越來越傾向於為合適的患者群體選擇經導管解決方案，而外科中心則繼續投資於支持混合治療途徑的先進瓣膜保留技術。

對製造規模、精準創新和夥伴關係主導的臨床檢驗如何構成成功瓣膜公司核心競爭優勢的策略性回顧

組織瓣膜領域的競爭動態反映了現有企業在擴大生產規模和臨床支援方面與新興企業在組織處理、輸送系統和病患選擇工具方面不斷創新之間的平衡。那些投資於垂直整合生產、廣泛的臨床培訓網路和完善的監管資源的市場領導，受益於與醫院系統和支付方建立的穩固關係。這些企業往往專注於在耐用性、穩健的供應鏈和全面的服務方面進行漸進式改進，從而減輕醫療服務提供者的手術全期負擔。

一項切實可行的策略議程，整合了製造韌性、流程最佳化和循證商業化，旨在加速技術應用並降低營運風險。

產業領導者應採取多管齊下的策略方法，將科學進步轉化為永續的優勢。首先，應優先考慮採購和生產的韌性，具體措施包括擴大區域加工能力、建立檢驗的合作夥伴網路，以及投資模組化製造，以便在需求波動時能夠靈活切換自體移植和異質骨移植的加工。其次，應使產品開發與外科手術趨勢保持一致，最佳化瓣膜結構，使其既適用於外科手術也適用於經導管輸送，確保提高耐久性的同時不會影響輸送性能或抗壓合性能。

我們採用透明、多方面的調查方法，結合面對面的專家訪談、臨床文獻綜述和比較過程分析，以確保獲得基於證據的見解。

本簡報的研究結合了多種定性和定量方法，旨在對生物瓣膜動力學提供全面、可靠的三角觀點。主要研究包括對心臟外科醫生、介入性心臟病專家、採購主管和監管專家進行結構化訪談，以收集第一線營運洞察和採購決策依據。此外，還與製造和供應鏈主管進行了深入討論，以了解產能限制、認證週期和關稅政策變化帶來的實際影響。

一份簡潔、全面的分析報告，重點闡述了技術創新、臨床證據和營運靈活性如何共同決定實施的成功和長期價值。

本執行摘要闡述了正在轉型中的行業現狀：材料科學的進步、手術流程偏好的轉變以及政策的調整相互交織，共同重塑著商業和臨床決策。組織處理技術和器械介面設計的持續創新正在重塑人們對長期性能的預期，而經導管和微創治療途徑的出現則擴大了患者覆蓋範圍，並改變了醫院的工作流程。同時，貿易政策和關稅趨勢凸顯了區域製造和供應鏈柔軟性的策略價值，促使企業重新調整資本和籌資策略。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • CXO觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新たな商機
  • 次世代經營模式
  • 産業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • ポーターの五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESGとサステナビリティ分析
  • ディスラプションとリスクシナリオ
  • 投資報酬率和成本效益分析

第6章 美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 按組織材料分類的人工生物瓣膜市場

  • 同種移植弁
    • 冷凍保存
    • 去細胞化
  • 異質骨移植
    • 牛源
    • ブタ由来

9. 依植入方式分類的人工生物瓣膜市場

  • 外科
    • 微創
    • 開胸置換術
  • 經導管
    • 經主動脈
    • 頂端
    • 經股動脈

第10章 按瓣膜位置分類的人工生物瓣膜市場

  • 主動脈瓣
  • 二尖瓣
  • 肺動脈瓣
  • 三尖瓣

第11章 按最終用戶分類的人工生物瓣膜市場

  • 門診手術中心
  • 醫院
  • 專科診所

第12章 區域性生物人工瓣膜市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 按組別分類的人工生物瓣膜市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國人工生物瓣膜市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 美國生物人工瓣膜市場

第16章：中國人工生物瓣膜市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Artivion, Inc.
  • Boston Scientific Corporation
  • Braile Biomedica
  • Colibri Heart Valve
  • Corcym
  • Edwards Lifesciences
  • Foldax, Inc.
  • Jenavalve Technology, Inc.
  • Labcor Laboratorios Ltda
  • Lepu Medical Technology Co., Ltd.
  • LifeNet Health
  • LivaNova PLC
  • Medtronic plc
  • TTK Healthcare Limited
Product Code: MRR-9A6A6F297853

The Artificial Biological Valve Market was valued at USD 8.30 billion in 2025 and is projected to grow to USD 8.72 billion in 2026, with a CAGR of 5.32%, reaching USD 11.93 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.30 billion
Estimated Year [2026] USD 8.72 billion
Forecast Year [2032] USD 11.93 billion
CAGR (%) 5.32%

An incisive overview framing clinical imperatives, material innovations, and strategic decision drivers that define the future trajectory of biological valve care

The artificial biological valve landscape is at an inflection point driven by converging clinical demands, technological innovation, and evolving care pathways. This executive summary synthesizes cross-disciplinary insights so that clinicians, manufacturers, payers, and investors can understand the forces reshaping valve selection, deployment approaches, and lifecycle management. Rather than present raw figures, the narrative focuses on structural drivers, operational implications, and the strategic responses that are proving most effective across diverse healthcare systems.

As pressure on cardiovascular services intensifies, decision-makers require actionable synthesis that bridges bench science and bedside realities. This introduction establishes the analytical frame: an emphasis on material science developments, procedural modality shifts, regulatory and reimbursement dynamics, and the interplay between supply chain resilience and clinical adoption. With those dimensions in view, subsequent sections examine transformative shifts, tariff-related disruptions in the United States, segmentation nuances, regional patterns, competitive behavior, recommended courses of action for industry leaders, and the methodological approach undergirding the research.

Taken together, this introduction positions the reader to interpret downstream analysis with a clear understanding of scope, purpose, and the practical lenses applied. The goal is to enable immediate application of insights to strategic planning, product development prioritization, and stakeholder engagement initiatives.

A comprehensive look at how material science breakthroughs, procedural innovation, and regulatory shifts are redefining clinical pathways and commercial value in valve therapy

The biological valve sector is undergoing transformative shifts that extend beyond incremental product improvements and into fundamental changes in how valves are developed, selected, and delivered. Advances in tissue processing and preservation have reduced time-zero immunogenicity and extended functional durability, while novel anti-calcification chemistries and matrix-stabilizing techniques are changing expectations for long-term performance. Concurrently, improvements in imaging, computational modeling, and device sizing have enabled tighter peri-procedural planning and lower complication rates, catalyzing wider acceptance of less invasive approaches.

At the same time, procedural innovation has redefined clinical pathways. Transcatheter techniques, refined delivery systems, and procedural standardization have lowered thresholds for intervention among older and higher-risk populations. This shift is reshaping the interplay between surgical teams and interventional cardiology, influencing hospital workflows and perioperative resource allocation. In parallel, supply chain modernization-driven by on-demand manufacturing capabilities, stronger cold-chain logistics, and regional sourcing strategies-has improved reliability but introduced new complexity in supplier qualification and regulatory oversight.

Regulatory bodies are responding to these changes with more adaptive approval pathways and a greater emphasis on real-world evidence collection, influencing post-market surveillance obligations and data infrastructure investments. Financial stakeholders are increasingly focused on reimbursement alignment with procedural outcomes and total cost of care, prompting manufacturers to offer outcome-linked contracts and extended support programs. Taken together, these transformative shifts create an environment where speed-to-clinic, clinical evidence generation, and integrated service models determine competitive advantage.

An evidence-based analysis of how 2025 tariff changes reshaped procurement, manufacturing localization, and clinical purchasing dynamics for biological valves

The imposition of new tariffs in the United States during 2025 has a cumulative effect that ripples across supply chains, procurement strategies, and pricing structures in the biological valve sector. At the transactional level, increased duties on imported tissue-processing supplies and finished bioprosthetic components elevated landed costs and forced many manufacturers to re-evaluate sourcing strategies. As a result, procurement teams have shifted toward more diversified supplier bases and nearshoring where feasible, while clinical teams have engaged more intensely with vendors to stabilize lead-times and service commitments.

Over time, these tariff-driven cost pressures amplified the importance of manufacturing scale, vertical integration, and regional production capacity. Organizations with in-region processing facilities or captive supply chains experienced fewer operational disruptions, while those dependent on distant suppliers confronted longer qualification cycles and greater inventory buffers. Consequently, capital allocation decisions increasingly prioritized resilient manufacturing footprints and multi-sourcing arrangements over marginal product enhancements.

Clinically, the tariffs influenced device selection dialogues within purchasing committees and hospital formularies, where the total cost of implant and associated peri-procedural expenses were scrutinized more closely. Payers and health systems sought stronger value propositions, prompting manufacturers to expand service offerings, warranty terms, and post-procedural outcome support. Finally, the tariffs accelerated collaboration between industry and regulators to clarify classification and duty treatment for advanced tissue technologies, underscoring that trade policy can be a persistent determinant of operational strategy and long-term competitiveness.

A layered segmentation perspective connecting tissue substrates, procedural routes, anatomical targets, and care settings to product design and market strategy imperatives

Understanding segmentation is central to interpreting demand drivers and innovation priorities in the biological valve market, and a layered view across tissue material, implantation method, valve position, and end user reveals distinct imperatives for product design and commercialization. Tissue material distinctions between homograft and xenograft create divergent development paths: homograft options, whether cryopreserved or decellularized, emphasize immunologic compatibility and native geometry preservation, while xenograft pathways, including bovine and porcine substrates, prioritize scalability and standardized processing protocols. These material choices have procedural consequences because tissue handling, storage requirements, and intraoperative behavior differ between preserved human tissues and sustainably sourced animal-derived leaflets.

Implantation method further refines competitive positioning. Surgical approaches, both minimally invasive and open replacement, demand designs optimized for suture techniques, hemostasis, and intraoperative adaptability, whereas transcatheter modalities-across transaortic, transapical, and transfemoral routes-require low-profile delivery systems, crimping resilience, and rapid deployment reliability. Valve position matters as well, with aortic implants facing distinct hemodynamic stresses and durability expectations compared with mitral, pulmonary, and tricuspid applications, each presenting bespoke anchoring and sealing challenges. Finally, end users-ranging from ambulatory surgery centers to hospitals and specialized clinics-exert differential requirements for logistics, training, and post-operative follow-up, influencing packaging, on-site technical support, and educational investments by manufacturers.

Taken together, these segmentation layers produce overlaying constraints and opportunities: product teams must balance tissue biology with mechanical demands, clinicians must select modalities aligned with institutional capabilities, and commercial leaders must map go-to-market approaches to the specific needs of ambulatory centers, high-throughput hospitals, or niche specialty clinics.

A regionally differentiated assessment of adoption, reimbursement, and manufacturing strategies that influence how valve innovations scale across global healthcare systems

Regional dynamics shape how innovations in biological valve technology are adopted, reimbursed, and supported, and a tripartite lens across the Americas, Europe, Middle East & Africa, and Asia-Pacific clarifies distinct opportunities and constraints. In the Americas, clinical systems emphasize procedural throughput and outcome transparency, with integrated health networks prioritizing technologies that reduce length of stay and readmission risk. Physicians and administrators in this region increasingly favor transcatheter solutions for appropriate patient cohorts, while surgical centers continue to invest in advanced valve preservation techniques that support hybrid procedural pathways.

Across Europe, Middle East & Africa, regulatory harmonization and diverse payer models create a mosaic of adoption timelines, where centralized HTA bodies and regional reimbursement policies influence procurement cadence. Healthcare delivery in various jurisdictions values long-term durability and robust clinical evidence, prompting manufacturers to generate region-specific real-world data and engage closely with hospital systems to align value demonstrations with national purchasing priorities. Meanwhile, in the Asia-Pacific region, rapid capacity expansion, growing cardiology specialization, and significant investments in domestic manufacturing have accelerated both surgical and transcatheter uptake. Local production capabilities and evolving regulatory frameworks in several countries encourage partnerships and technology transfer arrangements to meet regional demand while addressing cost sensitivity.

These regional characteristics underscore that global strategies must be adapted: supply chain planning, clinical engagement models, and evidence-generation efforts should be tailored to the procurement norms, clinical capabilities, and policymaker expectations that vary across the Americas, Europe, Middle East & Africa, and Asia-Pacific.

A strategic review of how manufacturing scale, targeted innovation, and partnership-driven clinical validation form the competitive core of successful valve enterprises

Competitive dynamics in the biological valve arena reflect a balance between incumbents scaling manufacturing and clinical support, and emerging challengers introducing discrete innovations in tissue processing, delivery systems, and patient selection tools. Market leaders that have invested in vertically integrated production, extensive clinical training networks, and broad regulatory dossiers benefit from established relationships with hospital systems and payers. These organizations tend to focus on incremental improvements in durability, supply chain robustness, and bundled service offerings that reduce peri-procedural complexity for care providers.

At the same time, nimble entrants and specialist developers are differentiating through targeted innovation: advanced decellularization platforms, proprietary anti-calcification chemistries, and delivery systems engineered for specific anatomical positions. Such firms often leverage partnerships with academic centers to accelerate clinical validation and use strategic collaborations to access distribution channels. Intellectual property around processing techniques and device interface design is a key asset, and portfolio diversification-spanning homograft processing services, xenograft leaflets, and transcatheter delivery platforms-improves resilience against single-product risk.

Investors and strategic buyers are attracted to companies that can demonstrate clinical differentiation, regulatory readiness, and the operational capacity to scale. As a result, merger and acquisition activity, licensing agreements, and co-development partnerships remain central to competitive playbooks. The overall strategic implication is clear: organizational success increasingly depends on integrating clinical evidence generation, robust manufacturing, and tailored commercial models that align with provider and payer expectations.

Actionable strategic imperatives combining manufacturing resilience, procedural optimization, and evidence-led commercialization to accelerate adoption and reduce operational risk

Industry leaders must adopt a multi-dimensional playbook to convert scientific advances into sustainable advantage. First, prioritize resilience in sourcing and production by expanding regional processing capacity, pursuing validated partner networks, and investing in modular manufacturing that can switch between homograft and xenograft processing when demand profiles shift. Second, align product development with procedural trends by optimizing valve constructs for both surgical and transcatheter delivery, ensuring that durability gains do not compromise deliverability or crimping resilience.

Third, deepen clinical partnerships to generate real-world evidence that supports reimbursement conversations and informs iterative product improvements. Establishing post-market registries and pragmatic outcome studies enables rapid feedback loops between clinicians and design teams and strengthens value propositions to payers. Fourth, adopt differentiated commercial models that reflect the needs of ambulatory surgery centers, high-volume hospitals, and specialized clinics; bundled service agreements, outcome-linked pricing, and on-site training programs can materially influence purchasing decisions and procedural adoption.

Finally, embed regulatory strategy and health economics early in development to reduce approval timelines and demonstrate comparative value. Proactive engagement with regulatory bodies and payer advisory panels will clarify evidence expectations and can streamline post-approval obligations. Taken together, these actions will help organizations reduce operational risk, accelerate adoption, and maintain alignment with evolving clinical practice.

A transparent, multi-method research approach combining primary expert interviews, clinical literature review, and comparative process analysis to ensure evidence-based insights

The research underpinning this summary combines multiple qualitative and quantitative approaches to ensure a robust, triangulated perspective on biological valve dynamics. Primary research included structured interviews with cardiac surgeons, interventional cardiologists, procurement leaders, and regulatory specialists to capture frontline operational insights and procurement rationales. These conversations were complemented by in-depth consultations with manufacturing and supply chain executives to understand capacity constraints, qualification cycles, and the practical implications of tariff policy changes.

Secondary sources comprised peer-reviewed clinical literature, regulatory guidance documents, patent filings, device labeling, and publicly available clinical registries, which were used to validate procedural trends and device performance claims. Where appropriate, anonymized case studies illustrating adoption patterns and hospital decision-making were synthesized to contextualize strategic recommendations. Data quality assurance included cross-validation of interview findings against documented clinical outcomes and triangulation across multiple independent sources to reduce bias.

Analytical techniques involved thematic coding of qualitative inputs, scenario-based impact assessment for policy shifts, and comparative process mapping to highlight friction points across implantation methods and end-user settings. The methodology emphasizes transparency, replicability, and pragmatic orientation, focusing on actionable insight generation rather than speculative forecasting.

A concise synthesis underscoring how technical innovation, clinical evidence, and operational agility together determine successful adoption and long-term value

This executive synthesis highlights a sector in transition where material science advancements, evolving procedural preference, and policy shifts intersect to redefine commercial and clinical decision-making. Durable innovation in tissue processing and device interface design is reshaping expectations for long-term performance, while transcatheter and minimally invasive pathways are expanding the pool of treatable patients and altering hospital workflows. Concurrently, trade policy and tariff developments have emphasized the strategic value of regional manufacturing and supply chain flexibility, prompting reprioritization of capital and procurement strategies.

For stakeholders across the value chain, the imperative is to integrate clinical evidence generation, manufacturing resilience, and tailored commercial models into a cohesive strategy. Organizations that combine technical differentiation with strong clinical partnerships and adaptive go-to-market approaches will be best positioned to capture emerging opportunities and mitigate operational risks. Ultimately, the combination of rigorous clinical validation, operational agility, and close alignment with care providers and payers will determine which innovations achieve durable adoption and deliver measurable improvements in patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Artificial Biological Valve Market, by Tissue Material

  • 8.1. Homograft
    • 8.1.1. Cryopreserved
    • 8.1.2. Decellularized
  • 8.2. Xenograft
    • 8.2.1. Bovine
    • 8.2.2. Porcine

9. Artificial Biological Valve Market, by Implantation Method

  • 9.1. Surgical
    • 9.1.1. Minimally Invasive
    • 9.1.2. Open Replacement
  • 9.2. Transcatheter
    • 9.2.1. Transaortic
    • 9.2.2. Transapical
    • 9.2.3. Transfemoral

10. Artificial Biological Valve Market, by Valve Position

  • 10.1. Aortic
  • 10.2. Mitral
  • 10.3. Pulmonary
  • 10.4. Tricuspid

11. Artificial Biological Valve Market, by End User

  • 11.1. Ambulatory Surgery Centers
  • 11.2. Hospitals
  • 11.3. Specialized Clinics

12. Artificial Biological Valve Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Artificial Biological Valve Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Artificial Biological Valve Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Artificial Biological Valve Market

16. China Artificial Biological Valve Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Artivion, Inc.
  • 17.7. Boston Scientific Corporation
  • 17.8. Braile Biomedica
  • 17.9. Colibri Heart Valve
  • 17.10. Corcym
  • 17.11. Edwards Lifesciences
  • 17.12. Foldax, Inc.
  • 17.13. Jenavalve Technology, Inc.
  • 17.14. Labcor Laboratorios Ltda
  • 17.15. Lepu Medical Technology Co., Ltd.
  • 17.16. LifeNet Health
  • 17.17. LivaNova PLC
  • 17.18. Medtronic plc
  • 17.19. TTK Healthcare Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY CRYOPRESERVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY CRYOPRESERVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY CRYOPRESERVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY DECELLULARIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY DECELLULARIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY DECELLULARIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY BOVINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY BOVINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY BOVINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY PORCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY PORCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY PORCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY OPEN REPLACEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY OPEN REPLACEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY OPEN REPLACEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSAORTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSAORTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSAORTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSAPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSAPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSAPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSFEMORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSFEMORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSFEMORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY AORTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY AORTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY AORTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY MITRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY MITRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY MITRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY PULMONARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY PULMONARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY PULMONARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRICUSPID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRICUSPID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRICUSPID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. GCC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GCC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 155. GCC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 156. GCC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 157. GCC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 158. GCC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 159. GCC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 160. GCC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 161. GCC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. G7 ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. G7 ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 182. G7 ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 183. G7 ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 184. G7 ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 185. G7 ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 186. G7 ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 187. G7 ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 188. G7 ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. NATO ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. NATO ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 191. NATO ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 192. NATO ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 193. NATO ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 194. NATO ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 195. NATO ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 196. NATO ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 197. NATO ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)